Search Results for "Poverty Guidelines, Research"
Displaying 1 - 20 of 30 results. 20 results shown per page. Page 1 of 2.
Inflation Reduction Act Research Series: Projected Impacts for Women Enrolled in Medicare
Publication Date
The Inflation Reduction Act (IRA) is helping people with Medicare, including nearly 30 million women enrolled in Part D. Our review shows that, in 2020, about 733,000 women enrolled in Part D and B would have benefited from the IRA’s $35 insulin cap and, in 2021, about 2 million women would not have had any out-of-pocket costs for recommended adult vaccines covered by Part D.
Inflation Reduction Act Research Series: Projected Impacts for Rural Medicare Enrollees
Publication Date
The Inflation Reduction Act (IRA) is helping people with Medicare, including over 8 million Part D enrollees who reside in rural areas. This fact sheet outlines the potential impacts of the IRA’s key drug-related provisions for rural Medicare enrollees.
Inflation Reduction Act Research Series: Medicare Part B Inflation Rebates in 2023
Publication Date
The Inflation Reduction Act (IRA) includes provisions to increase accessibility and affordability of prescription drugs for the 65 million Medicare beneficiaries, reduce the rate of growth in Medicare drug spending, and improve the financial sustainability of the Medicare program. These IRA provisions include a rebate on certain Part B and D drug prices if prices rise faster than inflation.
Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program
Publication Date
The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.
Inflation Reduction Act Research Series: Projected Impacts for Asian, Black, and Latino Medicare Enrollees
Publication Date
The Inflation Reduction Act (IRA) is helping people with Medicare afford their medications, including the 2.1 million Asian, 5.8 million Black, and 5.3 million Latino Part D enrollees. These fact sheets review existing research to present the projected impacts of key IRA Medicare drug-related provisions for these populations.
Research
Publication Date
Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Department of Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson issued a proposed rule, “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on
Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing
Publication Date
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated enrollee cost-sharing for recommended vaccines covered under Medicare Part D. In 2021, 3.4 million people received vaccines under Part D, and annual out-of-pocket costs were $234 million.
Analysis of Market Challenges for Antimicrobial Drug Development in the United States
Publication Date
The market for antimicrobial (AM) drugs is unique in that it is associated with a positive externality (public health) as well as a negative externality (antimicrobial resistance, or AMR) (Mossialos, et al., 2010). AMR occurs when microbes change over time and no longer respond to available medicine.
The Inflation Reduction Act of 2022: One Year Anniversary Highlights from ASPE Drug Pricing Reports
Publication Date
Introduction
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
Publication Date
The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.
International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies
Publication Date
Key Findings
Policy discussion surrounding U.S. prescription drug prices focuses on whether prices in the United States are too high or appropriate relative to the benefits that they offer to patients.
Assessing Relationships between Drug Shortages in the United States and Other Countries
Publication Date
Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.
Publication Date
Executive Summary
Prescription drugs play an ever-increasing role in modern medicine. New medications are improving health outcomes and quality of life, replacing surgery and other invasive treatments, and quickening recovery for patients who receive these treatments. As important as prescription drugs are, not everyone has access to them.
Managing the Unmanageable: Drug Payment and Utilization Management Strategies in Physician Organizations
Publication Date
by Helene Levens Lipton, Ph.D. Institute for Health Policy Studies, Department of Clinical Pharmacy University of California at San Francisco
Prescription Drug Pricing Reports to Congress
Publication Date
In response to a request by the House Committee on Appropriations for the Secretary of Health and Human Services (HHS) to submit a drug pricing report, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) developed this report containing data and analyses related to prescription drug spending between 2006 and 2018 as well as prescription drugs benefiting from public funding
Drug Utilization Trends by Therapeutic Class
Publication Date
Prepared for the Office of the Assistant Secretary for Planning and Evaluation Conference on Prescription Drug Costs and Pricing August 8-9, 2000 By
Chart: Price Changes by Product - Text Version
Publication Date
Chart: Price Changes by Product, Post Blueprint Period in 2017 Compared to the Same Time Period in 2018
Report to Congress: Prescription Drug Pricing Report
Publication Date
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.
Medicare Part B Drug Spending
Publication Date
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
The U.S.
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
Publication Date
U.S. Department of Health and Human Services